Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Solid Tumors
Filter by Topic
Bladder Cancer
Breast Cancer
Colon Cancer
Colorectal Cancer
Gastric Cancer
Genitourinary Cancers
GI Cancers
Gynecologic Cancer
Head and Neck Cancer
Liver Cancer
Lung Cancer
Melanoma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Thyroid Cancer
Aprepitant Reduces Cough Severity in Patients with Lung Cancer
By
Meg Barbor, MPH
Lung Cancer
,
Solid Tumors
December 2015, Vol 6, No 11
Boston, MA—In a first-of-its-kind study, aprepitant (Emend), a centrally acting neurokinin (NK)-1 antagonist indicated for the treatment of chemotherapy-induced nausea and vomiting (CINV), led to a reduction in cough frequency and an improvement in the objective and subjective measures of cough in patients with lung cancer.
Read Article
Genomic Test Supports Treatment Decisions in Prostate Cancer
By
Phoebe Starr
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
December 2015, Vol 6, No 11
San Antonio, TX—A genomic classifier is now available that can predict a low or high risk for metastasis in men with prostate cancer who have rising prostate-specific antigen (PSA) after a prostatectomy. The good news is that this test is reimbursable by Medicare.
Read Article
American Cancer Society Updates Breast Cancer Screening Guidelines for Women at Average Risk
By
Laura Morgan
Breast Cancer
,
Solid Tumors
December 2015, Vol 6, No 11
Breast cancer is the leading cause of premature death in women. According to the American Cancer Society (ACS), more than 40,000 US women will die of breast cancer in 2015.
Read Article
Patients with Early Breast Cancer and Low Oncotype DX Scores Can Skip Chemotherapy
By
Phoebe Starr
Breast Cancer
,
Solid Tumors
October 2015, Vol 6, No 9
Patients with early breast cancer and a low Onco
type
DX recurrence score can safely receive treatment with hormone therapy alone and avoid chemotherapy, according to results of the TAILORx trial, which was sponsored by the National Cancer Institute.
Read Article
80-Gene Assay Identifies Distinct Triple-Positive Breast Cancer Subtypes, Guides Therapy Selection
By
Corbin Davis
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
November 2015, Vol 6, No 10
San Francisco, CA—A new genetic test may allow clinicians to improve their therapy decisions by better categorizing patients into specific subtypes compared with conventional immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) subtyping. According to data presented at the 2015 Breast Cancer Symposium, the BluePrint 80-gene assay reclassifies approximately 23% of tumors, allowing for more effective therapy selection, particularly in patients with triple-positive (HER2-positive/hormone receptor–positive) disease.
Read Article
Men’s Health Supplements Have No Value for Patients with Prostate Cancer
By
Phoebe Starr
Prostate Cancer
,
Solid Tumors
November 2015, Vol 6, No 10
San Antonio, TX—Supplements that are often sold in supermarkets and health food stores to promote “men’s health” or “prostate health” do not provide any clinical benefits to men with prostate cancer, according to the results of a retrospective study presented at the 2015 American Society for Radiation Oncology annual meeting. Men’s health supplements did not significantly prevent distant metastasis, prostate cancer–related death, or treatment-related adverse events in this first-of-its-kind study.
Read Article
Controlled Ovarian Hyperstimulation Safe in Patients with Breast Cancer
By
Alice Goodman
Breast Cancer
,
Solid Tumors
September 2015, Vol 6, No 8
Boston, MA—Fertility preservation by controlled ovarian hyperstimulation with concurrent letrozole (Femara) is safe in women with breast cancer, according to a single-center, prospective study on the long-term safety of fertility preservation by the use of ovarian stimulation and concurrent aromatase inhibitors in women with breast cancer, presented at the 2015 Best of ASCO meeting in Boston. Controlled ovarian hyperstimulation had no impact on relapse-free survival and enabled live births in a substantial proportion of women who later chose to retrieve their frozen embryos or oocytes.
Read Article
PROCLAIM Study Fails to Identify Best Regimen for Locally Advanced Lung Cancer
By
Alice Goodman
Lung Cancer
,
Solid Tumors
September 2015, Vol 6, No 8
Boston, MA—What is the best chemotherapy regimen to use for patients with locally advanced nonsquamous non–small-cell lung cancer (NSCLC)? The phase 3 PROCLAIM trial attempted to answer this question, but the study failed to determine the best regimen for this patient population.
Read Article
SELECT: Lenvatinib Improves Outcomes as First-Line Treatment in Older Patients with Thyroid Cancer
By
Alice Goodman
Solid Tumors
,
Thyroid Cancer
September 2015, Vol 6, No 8
Chicago, IL—Lenvatinib (Lenvima) was approved by the FDA in February 2015 for the treatment of patients with advanced radioactive iodine (
131
I)-refractory differentiated thyroid cancer based on the SELECT trial results. Investigators looked at which patients will preferentially benefit from this oral tyrosine kinase inhibitor (TKI). At the 2015 American Society of Clinical Oncology meeting, 2 subgroup analyses of SELECT shed light on patient selection for treatment with lenvatinib.
Read Article
Medical and Psychosocial Impact of Oral Therapy on Patients with Metastatic Castration-Resistant Prostate Cancer
By
Laura Morgan
Prostate Cancer
,
Solid Tumors
September 2015, Vol 6, No 8
San Diego, CA—The introduction of 2 therapies for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC)—the orally administered abiraterone acetate (Zytiga) and enzalutamide (Xtandi)—has prompted Leslie Hazel-Fernandez, PhD, Comprehensive Health Insights, Louisville, KY, and colleagues to conduct a qualitative study to evaluate the personal and other factors that influence the use of oral drugs among patients with mCRPC, as well as to gauge caregivers’ and physicians’ experiences with patients who use these oral medications. The results of this study were presented at the 2015 Academy of Managed Care Pharmacy annual meeting.
Read Article
Page 8 of 16
3
4
5
6
7
8
9
10
11
12
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma